|
Affiliation |
Hospital Clinical Oncology |
Graduating School 【 display / non-display 】
-
-2019.03
Akita University Graduate School, Division of Medicine Graduated
-
-2011.03
Akita University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-2019.03
Akita University Graduate School, Division of Medicine Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2022.04-Now
Akita University Hospital Clinical Oncology Specially-appointed Assistant Professor
-
2020.08-2022.03
Akita University School of Medicine Endowed Departments Assistant Professor appointed to endowed chairs
External Career 【 display / non-display 】
-
2022.04
Akita University Hospital Clinical Oncology Specially-appointed Assistant Professor
-
2020.08-2022.03
Akita University School of Medicine Endowed Departments Assistant Professor appointed to endowed chairs
Research Achievements 【 display / non-display 】
-
Yoshida Taichi, Kodama Naoaki, Matsumoto Tomohiro, Taguchi Daiki, Shimazu Kazuhiro, Fukuda Koji, Shibata Hiroyuki
Internal Medicine ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 2025
<p>The optimal dose of chemotherapy for patients undergoing hemodialysis remains unclear. A 65-year-old man with diabetic nephropathy was treated with nivolumab plus modified FOLFOX6 therapy for recurrent gastric cancer with liver metastases. Oxaliplatin was reduced to 65 mg/m<sup>2</sup>, continuous infusion of 5-fluorouracil was initiated at 2,000 mg/m<sup>2</sup>, and bolus administration was discontinued. No nivolumab was administrated. Dose modification and discontinuation were performed depending on the patient's general condition and blood test during the treatment course. He received standard chemotherapy for gastric cancer; however, it was ineffective because of ascites and elevated CA125 levels. </p>